388 related articles for article (PubMed ID: 16302107)
1. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
2. DNA fingerprinting pattern and susceptibility to antifungal drugs in Cryptococcus neoformans variety grubii isolates from Barcelona city and rural environmental samples.
Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T; Baró-Tomás T; Alía-Aponte C; Lázera MS
Mycopathologia; 2005 Aug; 160(1):9-14. PubMed ID: 16160762
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
Espinel-Ingroff A; Canton E; Gibbs D; Wang A
J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
[TBL] [Abstract][Full Text] [Related]
4. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.
Pfaller MA; Zhang J; Messer SA; Brandt ME; Hajjeh RA; Jessup CJ; Tumberland M; Mbidde EK; Ghannoum MA
Antimicrob Agents Chemother; 1999 Jan; 43(1):169-71. PubMed ID: 9869586
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility characteristics of Cryptococcus neoformans varieties from AIDS patients in Goiânia, Brazil.
de F L Fernandes O; Passos XS; Souza LK; Miranda AT; Cerqueira CH; Silva Mdo R
Mem Inst Oswaldo Cruz; 2003 Sep; 98(6):839-41. PubMed ID: 14595465
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.
Nguyen MH; Yu CY
Antimicrob Agents Chemother; 1998 Feb; 42(2):471-2. PubMed ID: 9527812
[TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole.
Yildiran ST; Saracli MA; Fothergill AW; Rinaldi MG
Eur J Clin Microbiol Infect Dis; 2000 Apr; 19(4):317-9. PubMed ID: 10834825
[TBL] [Abstract][Full Text] [Related]
11. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study.
Borghi E; Iatta R; Sciota R; Biassoni C; Cuna T; Montagna MT; Morace G
J Clin Microbiol; 2010 Sep; 48(9):3153-7. PubMed ID: 20631105
[TBL] [Abstract][Full Text] [Related]
16. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.
Mondon P; Petter R; Amalfitano G; Luzzati R; Concia E; Polacheck I; Kwon-Chung KJ
Antimicrob Agents Chemother; 1999 Aug; 43(8):1856-61. PubMed ID: 10428902
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
18. [Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital].
Silva PR; Rabelo RA; Terra AP; Teixeira DN
Rev Soc Bras Med Trop; 2008; 41(2):158-62. PubMed ID: 18545836
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia.
Chandenier J; Adou-Bryn KD; Douchet C; Sar B; Kombila M; Swinne D; Thérizol-Ferly M; Buisson Y; Richard-Lenoble D
Eur J Clin Microbiol Infect Dis; 2004 Jun; 23(6):506-8. PubMed ID: 15141336
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirão Preto, São Paulo, Brazil.
Pedroso RS; Ferreira JC; Candido RC
Mem Inst Oswaldo Cruz; 2006 May; 101(3):239-43. PubMed ID: 16862315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
